In neuroblastoma, Miller’s group demonstrated that inhibition of TRPM2 increased the cytotoxicity of doxorubicin (Chen et al., 2014; Bao et al., 2016; Hirschler-Laszkiewicz et al., 2018; Bao et al., 2019; Hirschler-Laszkiewicz et al., 2022), a widely used anticancer drug in chemotherapy to treat various cancers (Minotti et al., 2004). The gene discussed is TRPM2; the disease is neuroblastoma.